Health & Wellness
How Is The New Glp Retatrutide Different From The Current Ones On The Market?
Retatrutide is in the final phases of becoming FDA-approved. Where semaglutide (Ozempic and Wegovy) only hit one receptor “GLP” and tirzepatide (Mounjaro and Zepbound) hit
February 26, 2026